IMNM: חוב לטווח קצר של החברה Immunome, Inc.

Immunome, Inc. (IMNM) is integrating ESG principles into the development of immune-based medicines, strictly adhering to bioethics and environmental safety. However, high acquisition risks and R&D expenditures pose a threat to liquidity, with the indicator standing at 0.00. The price action on GURU.Markets clearly demonstrates the market valuation of the company, which generates revenue through partnerships and plans to sell advanced antibodies for cancer treatment.

This indicator assesses the total volume of credit obligations due for repayment within twelve months. The dynamics of short-term financial liabilities allow for the determination of real liquidity and the risk of working capital deficits. The calculation is based on the sum of term loans and current debt obligations to creditors. For Immunome, Inc. (IMNM), a low debt level confirms financial stability. This ensures the resources necessary to develop the oncology pipeline and implement strategic partnerships.